vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
Scope
The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes - - Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan hepatitis B therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HBsAg release blocker, HBV DNA polymerase inhibitor, HBV DNA polymerase inhibitor and immunomodulator, HBV DNA polymerase inhibitor and microtubule assembly inhibitor, HBV therapeutic vaccine, HBV therapeutic vaccine and HBV DNA polymerase inhibitor, Hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, Immunomodulator, Protease inhibitor and others.- Analysis of the current and future competition in the seven key countries hepatitis B therapeutics market. Key market players covered are GlaxoSmithKline, Bristol-Myers Squibb, Daewoong Pharmaceutical Co., Ltd., Chongqing Jiachen Biotechnology Ltd, Chongqing Tongjunge Co., Ltd., LG Life Sciences, Ltd, Bristol-Myers Squibb Company, Phytrix Inc., Medivir AB, AiCuris GmbH & Co. KG, Gilead Sciences, Inc., VectorLogics, Inc., Genexine Co., Ltd., GenPhar
'/>"/>
SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team2.
Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)3.
Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 14.
United Therapeutics Corporation Reports Second Quarter 2012 Financial Results5.
Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing6.
United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 20127.
Juventas Therapeutics Raises $22.2 Million Series B Financing8.
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million9.
Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 201710.
Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest11.
Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report